Saturday, 17 November 2018
Latest news
Main » Active Stock You Need to Watch: Mannkind Corporation (MNKD)

Active Stock You Need to Watch: Mannkind Corporation (MNKD)

14 November 2017

Short shares increased from 23,671,860 to 26,337,802 over that period. The company has market cap of $368.74 million. These ratios are price to earnings, price to cash flow, EBITDA to EV, price to book value, and price to sales.

A number of equities analysts recently weighed in on the company. ValuEngine cut MannKind Corporation from a "hold" rating to a "sell" rating in a report on Wednesday, October 18th. Maxim Group reaffirmed a "buy" rating on shares of MannKind Corporation in a report on Friday, September 1st.

For Mannkind Corporation (NASDAQ:MNKD) out of the analyst recommendations 0 analysts recommend stock a Buy, 2 rate the stock Outperform, 0 analysts recommend to Hold the stock, 0 rate Underperform and 0 analysts recommend the stock a Sell. On October 10, 2017 HC Wainwright released a research note on MNKD with an initial rating of "Buy".

The ABR is the calculated average of the actual recommendations (strong buy, hold, sell etc.) made by the brokerage firms for the given stock.

On the other hand Mannkind Corporation (NASDAQ:MNKD) has Relative Strength Index (RSI 14) of 45.42 along with Average True Range (ATR 14) of 0.56.

In other news, Director Kent Kresa acquired 166,600 shares of the business's stock in a transaction that occurred on Friday, October 13th. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this link. Insiders own 1.60% of the company's stock. LMR Partners LLP purchased a new stake in MannKind Corporation during the 2nd quarter worth approximately $352,000. Wells Fargo & Company MN lifted its holdings in shares of MannKind Corporation by 51.5% in the third quarter. The company's past year sales total was 12400.

Michael Bisping has decided on the date of his retirement fight
I feel good, I'm in good shape, I've got no injuries, so why not? 'That wasn't the plan, but circumstances have put me in this situation'.

Shares of MannKind (NASDAQ:MNKD) were downgraded to a Hold by stock research analysts at Maxim Group. KCG Holdings Inc. lifted its holdings in shares of MannKind Corporation by 268.0% in the first quarter.

Trevena, Inc. (TRVN) stock moved with shift of 20.27% in the past week.

Analysts are also projecting an Average Revenue Estimate for MannKind $4430 in the Current Quarter.

For the Current Quarter, the growth estimate for MannKind -137.5%, while for the Next Quarter the stock growth estimate is -52.9%. Institutional investors own 14.59% of the company's stock.

Shares of MannKind Corporation (NASDAQ:MNKD) traded down $0.02 on Monday, reaching $3.24. Developed by hedge fund manager Joel Greenblatt, the intention of the formula is to spot high quality companies that are trading at an attractive price. Earnings, with 2 analysts believing the company would generate an Average Estimate of $-0.21. MannKind Corporation has a twelve month low of $0.67 and a twelve month high of $6.96. During previous trade 6.26 Million shares of Mannkind Corporation (NASDAQ:MNKD) exchanged hands whereas on average nearly 8.25 Million shares has been traded. The biopharmaceutical company reported ($0.31) EPS for the quarter, missing the Zacks' consensus estimate of ($0.20) by ($0.11). MannKind Corporation had a negative return on equity of 24.93% and a negative net margin of 155.83%. Short-term as well long term investors always focus on the liquidity of the stocks so for that concern, liquidity measure in recent quarter results of the company was recorded 1.80 as current ratio and on the opponent side the debt to equity ratio was 0.12 and long-term debt to equity ratio also remained 0.10. During the same quarter in the previous year, the company posted $1.30 earnings per share. The Price to Book ratio for MannKind Corporation NasdaqGM:MNKD is -1.372182.

WARNING: This article was posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this report on another site, it was stolen and republished in violation of United States & worldwide copyright legislation. MannKind Corporation (NasdaqGM:MNKD) has a current MF Rank of 16368. Its product candidate is AFREZZA, which is an inhaled insulin used to control high blood sugar in adults with type I and type II diabetes and helps in glycemic control.